In the News
GSK hit by fine for anti-competitive behaviour
Graham Watson
12th February 2016
Quelle surprise - on being fined for anti-competitive behaviour, GSK deny the allegations and argue that they brought the drugs of their generic rivals to the market earlier, saving the NHS money. Quite why a profit-maximising firm would act in this fashion, I don't know but I'm smelling a rat not least because "the CMA pointed out that after generic paroxetine entered the market properly at the end of 2013, average prices for the drug fell more than 70% in two years. More here from the CMA website.
You might also like
Monopsony Power in Markets
Study Notes
Oligopoly and Examples of Price Fixing
Study Notes
Google accused of anti-competitive behaviour in the app industry
20th April 2016
Monopoly Power (MCQ Revision Questions)
Practice Exam Questions
Mergers and Consumer Welfare (Revision Essay Plan)
Practice Exam Questions
Monopoly (Online Lesson)
Online Lessons
Industry Profile: UK Cinema Industry
Topic Videos
